[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jonsson Comprehensive Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":583},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,70,0,25,[9,42,68,86,107,131,155,181,204,224,251,271,291,311,336,360,380,404,435,454,474,494,518,543,563],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100595457","a-disposable-negative-pressure-wound-therapy-device-snap-to-promote-wound-healing-in-the-lower-limbs-following-mohs-micrographic-surgery-for-non-melanoma-skin-cancer-100595457",false,"NCT07032701","A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer","Assessing the Impact of a Disposable Negative Pressure Wound Therapy Device on Surgical Wounds of the Lower Extremities Following Mohs Micrographic Surgery","Inclusion Criteria:\n\n* Aged 19 to 79 years\n* Presenting with a lower limb wound following Mohs surgery for non-melanoma skin cancer, designated to heal by secondary intention\n* Wound size less than 13 cm x 13 cm\n* Patient capable of changing the SNAP-therapy system at home\n\nExclusion Criteria:\n\n* History of diabetes mellitus\n* History of venous insufficiency\n* History peripheral arterial disease\n* Chronic steroid use (defined as great than 6 weeks) within the last one year\n* History of HIV\n* History of chemotherapy use within the last one year\n* History of smoking exceeding 10 pack-years or current smoker\n* History of stroke\n* History of deep venous thrombosis\n* Active infection\n* Allergy to adhesives\n* Wounds with visible bone, tendon, ligament, nerve","ALL","19 Years","79 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial studies whether a disposable negative pressure wound therapy (dNPWT) device, SNaP Wound Care System (Ultraportable Mechanically Powered Negative Pressure Wound Therapy) (SNaP), promotes wound healing in the lower limbs in patients that have undergone Mohs micrographic surgery (Mohs surgery) for non-melanoma skin cancer. Mohs surgery is a surgical technique used to treat skin cancer. Individual layers of cancerous tissue are removed and examined under a microscope one at a time until all cancerous tissue has been removed. It is an important part of removing skin cancer, but it often leads to soft-tissue defects and reconstructive challenges, especially in high-tension areas like the lower limbs. Typically, these wounds are managed by leaving them open and allowing them to heal from the base up or are reconstructed by transferring healthy skin from another part of the body. Negative pressure wound therapy (NPWT) is a wound dressing system that continuously or intermittently applies subatmospheric pressure to the surface of a wound to draw out fluid and promote healing. The SNaP device is a dNPWT device for lower leg wound healing designed for increased portability and ease of use outside of a hospital setting. It is a modification of traditional NPWT devices that uses springs to generate pressure, making it lighter and more user-friendly than traditional devices that rely on electrically powered pumps. This may be a more effective way to promote wound healing in the lower limbs following Mohs surgery for non-melanoma skin cancer.",[28],"Skin Carcinoma","NOT_YET_RECRUITING","2026-06-29",{"date":32,"type":33},"2026-07-01","ACTUAL",{"date":35,"type":22},"2026-12",{"date":37,"type":22},"2031-06",{"name":39,"class":40},"Jonsson Comprehensive Cancer Center","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100549286","phase-1-yttrium-90-y90-radioembolization-for-the-treatment-of-early-stage-renal-cell-carcinoma-the-renegade-trial-100549286","NCT06432036","Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial","RENEGADE: Radioembolization for Early Stage Renal Cell Carcinoma: An Open-Label, Prospective, Multi-Center, Phase 1\u002F2 Safety Trial","Inclusion Criteria:\n\n* Participants must be aged ≥ 18 years at the time of screening\n* Written informed consent and any locally required authorization (e.g., Health Insurance Portability and accountability Act) obtained from the patient\u002Flegal representative prior to performing any protocol-related procedures, including screening evaluations\n* Life expectancy ≥ 12 months\n* RCC, diagnosed by radiographic imaging and histology\n* Clinical stage of RCC: T1 or T2a, Cancer stage (N0M0)\n* 1-2 solid (\\> 80% solid) target lesions\n* Patient not an ideal candidate for partial nephrectomy or thermal ablation at the time of study entry, based on the decision of the institution's multidisciplinary tumor board. Contraindications for partial nephrectomy include inability to potentially partially resect the kidney, high risk of adverse events due to medical comorbidities, or potential high risk of adverse events due to general anesthesia. Contraindications to thermal ablation include potential inability to technically place ablation probes into the tumor, central tumors which risk thermal injury to the renal collecting system\n* Patient not considered a candidate for long-term active surveillance due to oncologic risk due to tumor growth and\u002For tumor size\n* Patient not considered ideal candidates for radical nephrectomy due to surgical comorbidity and\u002For development of adverse health outcomes\n* Measurable tumor by RECIST 1.1 criteria\n* Absence of bilateral renal tumors\n* Negative serum pregnancy test in females of child-bearing potential; patients who are breast-feeding cannot participate in this trial\n* Hemoglobin ≥ 9.0 g\u002FdL\n* Absolute neutrophil count ≥ 1.5 x 10\\^9\u002FL\n* Absolute lymphocyte count ≥ 1.0 x 10\\^9\u002FL\n* Platelet count ≥ 75 x 10\\^9\u002FL\n* Glomerular filtration rate (GFR) ≥ 45 mL\u002Fmin\u002F1.73 m\\^2\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment\n* Screening mapping angiogram demonstrates successful localization of tumor(s), where catheter placement location(s) would allow Y90 to distribute in the intended treatment area, without venous shunting\n\nExclusion Criteria:\n\n* Any contraindication to angiography or selective renal artery catheterization\n* Screening angiography with cone beam CT (CBCT) shows any arterial flow to the gastrointestinal tract uncorrectable by angiographic techniques\n* Screening angiography with CBCT shows poor tumor targeting that would lead to a dose that does not meet the renal dosing criteria. This typically occurs when a feeding artery to the tumor cannot be identified\n* Screening angiography demonstrates excessive non-tumoral renal parenchyma will be in the treatment field, that the new baseline glomerular filtration rate will be \\\u003C 45 mL\u002Fmin\u002F1.73 m\\^2\n* Screening angiography demonstrates renal venous shunting of iodinated contrast that is immediately visible upon arterial injection\n* Extra-renal metastases, including patients with abdominal lymph nodes \\>1.5 cm in shorter axis, or with lung nodules (single lesion, \\>1 cm, or multiple smaller lesions with a total diameter \\>2 cm)\n* Brain metastases, leptomeningeal carcinomatosis or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry\n* Evidence of any tumor invasion into the renal vein, renal artery, or renal collecting system\n* Any prior radiation therapy to the abdomen, including localized radiation therapy to the index tumor\n* Concurrent treatment for RCC or treatment in the last 6 months in another clinical study, unless it is an observational study (non-interventional) or during a non-interventional follow-up stage of an interventional study, or prior randomization to this study\n* History of active primary\u002Facquired immunodeficiency\n* Presence of renal ureteral stent in the treatment kidney at any time\n* History of malignancy, other than RCC, within three years, with the exception of adequately treatment carcinoma in situ of the cervix, early squamous cell carcinoma or basal cell carcinoma of the skin, localized prostate cancer, ductal carcinoma in situ, or low-grade endometrial carcinoma with no myometrial invasion (negligible risk of metastases or death 5-year overall survival \\[OS\\] rate \\> 90%)\n* Major surgical procedure (as defined by the Investigator) within 28 days prior to enrollment\n* A history of severe allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically\n* Active infection\n* Female patients who are pregnant or breastfeeding or female patients of reproductive potential who are not willing to employ effective birth control from screening to 6 months after treatment\n* Unstable chronic disease or evidence of any disease or condition that would place the patient at undue risk and preclude safe use of Y90 microspheres, including but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent\n* History of pulmonary insufficiency, measured by oxygen saturation of less than 90%\n* Solitary kidney\n* Patient not able to follow the study protocol requirements","18 Years",{"count":7,"type":22},[52,53],"PHASE1","PHASE2","This phase I\u002FII trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very tiny glass spheres. These spheres are injected into the artery that feeds the cancer. This process is called radioembolization. Y-90 radioembolization may be a safe and effective treatment for patients with early stage renal cell carcinoma.",[56,57],"Stage I Renal Cell Cancer","Stage II Renal Cell Cancer","RECRUITING","2026-06-26",{"date":61,"type":33},"2026-06-30",{"date":63,"type":33},"2024-12-26",{"date":65,"type":22},"2030-03",{"name":39,"class":40},2,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":41},"100644542","magnetic-resonance-guided-stereotactic-body-radiation-therapy-for-the-treatment-of-metastatic-solid-tumors-one-shot-trial-100644542","NCT07671768","Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Tumors, ONE SHOT Trial","ONE SHOT: Single-Fraction Adaptive MR-Guided Radiation Therapy for Metastatic Solid Tumors","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Histologically confirmed metastatic solid tumor (any primary site)\n* 1-3 metastases ≤ 5 cm each located outside the brain and spine\n* Lesions treatable at 25-30 Gy × 1 fraction with MR guidance\n* No overlapping prior radiation\n* Absolute neutrophil count (ANC) \\> 1.5 cell\u002Fmm\\^3\n* Hemoglobin (Hgb) \\> 8.0 gm\u002FdL\n* Platelet (PLT) \\> 150,000\u002Fmm\\^3\n* Total bilirubin \\\u003C or equal to 1.5 x upper limit of normal\n* Aspartate aminotransferase (AST) \\\u003C or equal to three times upper limit of normal\n* Alanine aminotransferase (ALT) \\\u003C or equal to three times upper limit of normal\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Uncontrolled infection or major comorbidity\n* Pregnant or breastfeeding\n* MRI contraindication\n* Life expectancy \\\u003C 3 months",{"count":7,"type":22},[25],"This clinical trial studies the side effects of magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT) and to see how well it works in treating patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. The total dose of radiation is divided into smaller doses given over 1-5 days. This type of radiation therapy helps spare normal tissue. During MR-guided SBRT, MR imaging is used to define and localize the area to be treated and provide more accurate delivery. This allows the treatment to be given over one day. MR-guided SBRT may be safe, tolerable, and\u002For effective in treating patients with metastatic solid tumors. Tumors in the central nervous system will not be treated on this study.",[79],"Metastatic Malignant Solid Neoplasm","2026-06-23",{"date":59,"type":33},{"date":32,"type":22},{"date":84,"type":22},"2038-07-01",{"name":39,"class":40},{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":41},"100550531","phase-3-ph-weighted-chemical-exchange-saturation-transfer-mri-based-surgical-resection-to-improve-survival-in-patients-with-glioblastoma-100550531","NCT06448286","PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma","PH Weighted Chemical Exchange Saturation Transfer Based Surgical Resections of Glioblastoma","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age\n* Documentation of a newly diagnosed World Health Organization (WHO) grade IV glioblastoma as evidenced by clinical features and imaging data\n* Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Male or female \\\u003C 18 years of age\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data\n* Not medically cleared for surgery\n* Previous treatment (any chemotherapy, molecular therapy, immunotherapy, or radiation therapy)",{"count":21,"type":22},[95],"PHASE3","This phase III trial compares pH weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI)-based surgical resections to standard of care surgical resections for the treatment of patients with glioblastoma. Standard of care therapy for glioblastoma is surgery to remove tumor tissue that enhances on standard MRI imaging, however, it has been shown that significant tumor burden exists in the region around the tumor tissue that does not enhance with standard MRI. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. These pictures can show the difference between normal and tumor tissue. CEST MRI is a technique that uses differences in the tissue environment, like protein concentration or intracellular pH, to generate contrast differences. CEST MRI may identify tumor tissue that does not enhance with standard of care MRI. PH weighted CEST MRI based surgical resection may be more effective compared to standard of care surgical resection in treating patients with glioblastoma.",[98],"Glioblastoma","2026-06-11",{"date":101,"type":33},"2026-06-15",{"date":103,"type":22},"2026-12-01",{"date":105,"type":22},"2030-06-01",{"name":39,"class":40},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":123,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":41},"100550440","phase-2-an-investigational-scan-89zr-dfo-gmab-petct-compared-to-contrast-enhanced-ct-for-the-detection-of-recurrent-clear-cell-renal-cell-cancer-after-surgery-comparing-carbonic-anhydrase-ix-caix-pet-ct-to-conventional-pet-ct-for-post-op-staging-in-kidney-cancer-100550440","NCT06447103","An Investigational Scan (89Zr-DFO-GmAb PET\u002FCT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer","89Zr-DFO-GmAb PET\u002FCT vs Contrast-Enhanced CT for Detection of Recurrent Clear Cell Renal Cell Carcinoma After Surgery","Inclusion Criteria:\n\n* Age ≥ 18\n* Histologically confirmed clear cell renal cell carcinoma (RCC) (ccRCC) (based on partial\u002Fradical nephrectomy\u002Fmetastasectomy)\n\n  * For tumors with extensive sarcomatoid features, if there is evidence of areas of clear cell and high CAIX expression throughout the tumor on immunohistochemistry, they will be allowed on study\n* Subjects must have undergone definitive treatment of their primary tumor (partial\u002Fradical nephrectomy) +\u002F- resection of metastatic disease to no evidence of disease (NED) with a prior nephrectomy \\\u003C 2 years)\n* Surgery must have been performed between 4-16 weeks at the time of planned imaging\n* Subjects are considered to have a high risk of recurrence based on the following criteria:\n\n  * Intermediate-high risk ccRCC:\n\n    * pathologic tumor stage 2 (pT2), grade 4, or sarcomatoid, N0, M0\n    * pathologic tumor stage 3 (pT3), any grade, N0, M0\n  * High risk ccRCC:\n\n    * pathologic tumor stage 4 (pT4), any grade, N0, M0\n    * pT any stage, any grade, number of positive nodes (pN+), M0\n  * M1 now NED: pathologically-confirmed ccRCC, undergoing a resection of a solitary, isolated soft tissue metastasis within two years from initial nephrectomy\n* Negative serum pregnancy tests in female patients of childbearing potential. (Women of child bearing potential \\[WOCBP\\] require a negative pregnancy test within 24 hours (urine) prior to receiving investigational product)\n* Consent to practice double-barrier contraception until a minimum of 42 days after 89Zr-DFO-GmAb administration\n* Individual must be able to remain still and lie flat for duration of the diagnostic imaging procedure (less than 1 hour)\n\nExclusion Criteria:\n\n* Inability to provide written informed consent\n* Any evidence of residual disease or known metastasis at the time of planned 89Zr-DFO-GmAb administration\n* Prior post-operative imaging for confirmation of disease status\n* An untreated non-renal malignancy with the following exceptions:\n\n  * Low risk prostate cancer on active surveillance (National Comprehensive Cancer Network \\[NCCN\\] very low\u002Flow risk)\n  * Non-melanoma skin cancer\n* Any prior treated malignancy meeting the following characteristics:\n\n  * Treated stage I or II cancer from which the patient is currently in complete remission\n  * A stage III cancer from which the patient is progressing or has been disease-free for and has required active treatment (e.g. adjuvant or maintenance therapy) within the past 3 years prior to enrollment\n  * A hematologic malignancy from which the patient is currently in complete remission\n* Contraindication to the use of iodinated contrast-enhanced CT agents, based on:\n\n  * Severe allergy (for which pre-medication cannot limit adverse reactions) or\n  * Estimated glomerular filtration rate (GFR) ≤ 30 ml\u002Fmin\u002F1.73m\\^2\n* Prior use of systemic therapy treatment for kidney cancer (PD-1, PD-L1, tyrosine kinase or TOR inhibitor) or radiotherapy within 4 weeks of enrollment\n* Exposure to experimental diagnostic or therapeutic drug within 14 days from date of planned administration\n* Women who are pregnant or breastfeeding\n* Known hypersensitivity to girentuximab\n* Known inability to remain still and lie flat imaging procedure (about 30 minutes)",{"count":115,"type":22},91,[53],"This phase II trial compares the safety and effectiveness of 89Zr-DFO-GmAb positron emission tomography (PET)\u002Fcomputed tomography (CT) compared to contrast-enhanced CT after surgery in detecting clear cell renal cell cancer that has come back (recurrent). For some patients, the risk of recurrence after surgery remains high. Conventional CT methods, such as contrast-enhanced CT, may not detect small volume or micrometastatic disease. PET\u002FCT with radiotracers, such as 89Zr-DFO-GmAb, may improve detection of tumor cells. Girentuximab (GmAb), a monoclonal antibody, is tagged with zirconium-89, a radioactive atom (which is also known as an isotope). The zirconium-89 (89Zr) isotope is attached to girentuximab with desferrioxamine (DFO) and this combined product is called 89Zr-DFO-girentuximab. 89Zr-DFO-girentuximab attaches itself to a protein on the surface of clear cell renal cell tumor cells called CAIX. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 89Zr-DFO-GmAb. Because some cancers, including clear cell renal cell cancer, take up 89Zr-DFO-GmAb it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. Using contrast agents with CT scan to enhance the images (contrast-enhanced CT) is standard of care imaging. 89Zr-DFO-GmAb PET\u002FCT may be safe and effective compared to contrast-enhanced CT in detecting recurrent clear cell renal cell cancer after surgery.",[119,120,57,121,122],"Clear Cell Renal Cell Carcinoma","Sarcomatoid Renal Cell Carcinoma","Stage III Renal Cell Cancer","Stage IV Renal Cell Cancer",[124],"Renal",{"date":101,"type":33},{"date":127,"type":33},"2024-08-06",{"date":129,"type":22},"2030-12-01",{"name":39,"class":40},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":138,"minAge":4,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":41},"100469860","phase-1-image-guided-biopsies-to-identify-mechanisms-of-resistance-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-177lu-psma-radioligand-therapy-100469860","NCT05398302","Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy","Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Mechanisms of Resistance in Patients Undergoing 177Lu-PSMA Radioligand Therapy","Inclusion Criteria:\n\n* Volunteer patient\n* Histologically confirmed prostate cancer\n* Eligible for 177Lu-PSMA-617 under expanded access protocol (IRB# 21-5010) or as part of an approved trial\n* Based on positron emission tomography (PET)\u002Fcomputed tomography (CT) images: Evidence of lymph node or soft tissue metastatic disease amenable to image-guided biopsy\n* Platelets \\> 75,000\u002Ful within 14 days prior to biopsy\n* Prothrombin time (PT) or International normalized ratio (INR) and a partial thromboplastin time (PTT) \\\u003C 1.5 times the institutional upper limit normal (ULN) within 14 days prior to biopsy\n* Patients on warfarin, aspirin, or other anti-coagulants are eligible provided they are deemed able to tolerate discontinuation of anti-coagulation for one week prior to the biopsy. Conversion to low molecular weight heparin prior to biopsy is permitted per local standard operating procedures, provided there is agreement regarding the procedure between the treating physician, the interventional radiologist and the principal investigator (PI)\n\nExclusion Criteria:\n\n* Patients with significant congenital or acquired bleeding disorders (e.g. von Wildebrand's disease, acquired bleeding factor inhibitors) are not eligible","MALE",{"count":140,"type":22},30,[52],"This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Diagnostic procedures, such as image guided biopsies, may help in learning how well 177Lu-PSMA works to kill tumor cells and allow doctors to plan better treatment.",[144,145,146,147,148],"Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8",{"date":101,"type":33},{"date":151,"type":33},"2024-04-26",{"date":153,"type":22},"2027-12-31",{"name":39,"class":40},{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":162,"minAge":49,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":41},"100643692","phase-2-elacestrant-with-everolimus-for-the-treatment-of-recurrent-advanced-or-metastatic-er-positive-endometrial-cancer-100643692","NCT07634601","Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer","A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)","Inclusion Criteria:\n\n* Must be ≥ 18 years of age\n* Ability to understand and the willingness to sign a written informed consent document. Patient must sign the informed consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Participants must have histologically confirmed advanced (International Federation of Gynecology and Obstetrics \\[FIGO\\] stage III or IV), persistent, or recurrent endometrial cancer (histologic documentation of recurrence not required) that has\n\n  * Patient's archival endometrial cancer tumor specimen has positive hormone receptor expression defined as \"positive\" or ≥ 1% by immunohistochemistry (IHC) performed at any Clinical Laboratory Improvement Act (CLIA)-certified laboratory\n  * Can be any histologic subtype including endometrioid, mixed, serous, clear cell, carcinosarcoma\n* Prior treatment with at least one line of platinum-based chemotherapy is required (can be in the adjuvant setting):\n\n  * Patients with mismatch repair deficiency (dMMR) tumors must have received at least one prior line of immunotherapy. An exception may be made for patients with documented contraindications to immunotherapy, including but not limited to severe autoimmune conditions, solid organ transplantation, or lack of access to immunotherapy.\n  * Prior exposure to to progestins, aromatase inhibitors, tamoxifen, selective estrogen receptor down regulator (SERD) is allowed if the last dose was ≥ 4 weeks before enrollment Availability of adequate archival tumor tissue (from initial biopsy, surgical specimen, or repeat biopsy) is preferred but not required for study entry. When available, archival tissue should consist of either one unstained slide cut at 4-5 µm or one formalin-fixed paraffin-embedded (FFPE) tissue block with one corresponding H\\&E slide, submitted per the Lab Manual. If archival tissue is not available, the participant may still be enrolled with Principal Investigator approval prior to study entry\n* No prior history of other malignancies within past 2 years (besides endometrial cancer as per Inclusion #4). Individuals with the following cancers are eligible if diagnosed and treated within the past 2 years: ductal carcinoma in situ of the breast, cervical cancer in situ, melanoma in situ, and basal cell or squamous cell carcinoma of the skin, early stage breast cancer or cervical cancer, early stage renal cell carcinoma or any other likely curatively treated early stage malignancy. No concurrent malignancy or other serious medical condition as deemed by the investigator\n* Patients who received chemotherapy or hormonal therapy must have recovered (Common Terminology Criteria for Adverse Events \\[CTCAE\\] grade ≤ 1) from the acute effects of chemotherapy except for residual alopecia or grade 2 peripheral neuropathy prior to enrollment. A washout period of at least 21 days is required between last chemotherapy dose and enrollment (provided the patient did not receive radiotherapy)\n* Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and cycle 1 day 1. Radiation therapy that is given for palliative purposes, e.g. for pain control or prevention of a tumor associated complication is allowed during the study, with the exclusion of thoracic radiation. However, study medication should be held during the duration of the radiation therapy and the radiated tumor lesion cannot be used for assessment of treatment response. Radiation therapy should not be administered before the first response assessment\n* Able to take study medication by mouth\n* Pre- and postmenopausal women are eligible. Premenopausal women of childbearing potential must have a negative serum pregnancy test at time of screening. Woman of childbearing potential (WOCBP) is defined as follows:\n\n  * Any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or a bilateral oophorectomy) OR\n  * Any female who is not postmenopausal defined as:\n\n    * Age ≥ 60 years; OR\n    * Age \\\u003C 60 with intact uterus AND amenorrhea for 12 consecutive months or more AND estrogen (estradiol) levels within postmenopausal range; OR\n    * Status-post bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation.\n\nIn the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential\n\n* Women of child-bearing potential must use highly effective methods of contraception throughout the study and for 120 days after study drug discontinuation. Highly effective contraception methods include:\n\n  * Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\n  * Female sterilization (surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n\nUse of non-hormonal methods of contraception or placement of an nonhormonal intrauterine device (IUD) or intrauterine system (IUS)\n\n* Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL (at screening)\n* Platelets ≥ 100 × 10\\^9\u002FL (at screening)\n* Hemoglobin ≥ 8.0 g\u002FdL (at screening)\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 3 x institutional upper limit of normal (ULN) (at screening)\n* Total serum bilirubin \\\u003C 1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN (at screening)\n* Patients with type 2 diabetes are eligible if on stable therapy and hemoglobin A1c ≤ 8%\n* Patients fasting triglycerides must be ≤ 300 mg\u002FdL\n* No evidence of clinically significant, active interstitial lung disease or pneumonitis on history or baseline imaging. Patients with pneumonitis related to radiation or prior therapies may be eligible at investigator discretion discretion if recovered at the time of study initiation\n* Patient can safely discontinue strong and moderate CYP3A4 inhibitors or inducers (e.g., certain azole antifungals, rifampin, some anticonvulsants) at least 14 days or 5 half lives whichever is shorter prior to first dose of study drug, or switch to acceptable alternatives\n\nExclusion Criteria:\n\n* Patients who have previously received everolimus or any another mTOR (mammilian target of rapamycin) inhibitor (eg. sirolimus, temsirolimus) for the treatment of endometrial cancer and are no longer receiving therapy with washout\n* Participants who are receiving any other anti-cancer approved or investigational agents within \\\u003C 21 days or 4 weeks if fulvestrant prior to cycle 1 day 1. Participation in other observational studies is permitted\n* Symptomatic brain metastases or carcinomatous meningitis. Patients with treated brain metastases may be eligible if they are asymptomatic and neurologically stable, and demonstrate radiographic stability at screening, confirmed at least 28 days following completion of definitive treatment (e.g., surgery and\u002For radiation therapy)\n* History of other malignancies within past 2 years, except ductal carcinoma in situ of the breast, cervical cancer in situ, melanoma in situ, basal cell or squamous cell carcinoma of the skin or early stage cancers deemed curable by investigator. No concurrent malignancy or other serious medical condition as deemed by the investigator\n* Herbal preparations\u002Fmedications are prohibited throughout the study. These herbal medications include, but are not limited to: St. John's wort, Kava, ephedra (ma huang), gingko biloba, black cohosh, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng. Patients should stop using these herbal medications 7 days prior to first dose of study drug\n* Patients receiving chronic treatment with systemic steroids (\\> 10mg prednisone equivalent) or another immunosuppressive agent\n* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment (e.g. estimated creatinine clearance \\\u003C 30ml\u002Fmin), symptomatic angina pectoris, cardiac arrhythmia, a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n\n  * Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea) are ineligible\n  * Patient with active systemic bacterial infection (requiring intravenous \\[IV\\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \\[for example, hepatitis B surface antigen positive\\])\n  * Screening for HIV and hepatitis is not required for enrollment\n* The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest\n* Any of the following within 6 months prior to trial registration: myocardial infarction, severe\u002Funstable angina pectoris, coronary\u002Fperipheral artery bypass graft, New York Heart Association (NYHA) class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism\n* History of hypersensitivity or intolerance to elacestrant, everolimus, other rapamycin analogs (eg. temsirolimus, sirolimus) or any of the components in either medication\n* Pregnant women are excluded from this study because embryo-fetal toxicity is a potential side effect of elacestrant and everolimus. For this reason, women of child-bearing potential (WOCBP) must agree to use highly effective contraception prior to study entry, for the duration of treatment, and for at least 120 days after the completion of treatment. Prior to study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy\n* Women of child-bearing potential, who will not use a highly effective method of contraception\n* Women who are lactating\n* Other severe acute or chronic medical or psychiatric condition, or significant laboratory abnormality requiring further investigation that may cause undue risk for the patient's safety, inhibit protocol participation, or interfere with interpretation of trial results, and in the judgment of the investigator would make the patient inappropriate for entry into this trial\n* Patients must be able to follow concomitant medication restrictions:\n\n  * Strong CYP3A4 inhibitor drugs, food and herbal products, including but not limited to: ceritinib, clarithromycin, cobicistat, danoprevir, dasabuvir, elvitegravir, idelalisib, itraconazole, ketoconazole, lopinavir, nefadozone, nelfinavir, ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telithromycin, tipranavir, troleandomycin, voriconazole\n  * Moderate CYP3A4 inhibitor drugs, food and herbal products, including but not limited to: amprenavir, aprepitant, atazanavir, casopitant, cimetidine, ciprofloxacin, conivaptan, crizotinib, cyclosporine, darunavir, darunavir\u002Fritonavir, diltiazem, dronedarone, erythromycin, faldaprevir, fluconazole, fluvoxamine, fosamprenavir, imatinib, isavuconazole, letermovir, netupitant, nilotinib, octreotide, tofisopam, verapamil\n  * Strong CYP3A4 inducer drugs, food and herbal products, including but not limited to: carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifampin, rifabutin\n  * Moderate CYP3A4 inducer drugs, food and herbal products, including but not limited to: bosentan, dabrafenib, efavirenz, etravirine, lesinurad, lopinavir, metamizole, modafinil, nafcillin, thioridazine, tipranavir\u002Fritonavir, telotristat ethyl\n  * Herbal preparations, including, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, DHEA, yohimbe, saw palmetto, and ginseng\n  * Grapefruit, grapefruit juice, and grapefruit-containing beverages and other foods known to inhibit CYP3A4 and P-gp activity\n* Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period. Close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus. Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Guérin (BCG), yellow fever, varicella and TY21a (Typhoid Vaccine Live Oral Ty21a) typhoid vaccines\n* Patients with rare hereditary disorders of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption are excluded, as everolimus contains lactose\n* Patients who require use of systemic corticosteroids is prohibited with the following exceptions:\n\n  * Participants on a stable or decreasing dose of corticosteroids at baseline for management of brain metastasis.\n  * Low dose systemic corticosteroids are needed to manage certain conditions (e.g., rheumatoid arthritis) if the dose is not expected to lead to moderate or strong CYP3A4 induction.\n  * Single doses, topical applications (including mouthwashes), inhaled sprays, eye drops, and local injections are allowed.\n  * Systemic short-term steroids are also allowed for treatment of adverse events (AEs)","FEMALE",{"count":164,"type":22},50,[53],"This phase II trial tests how well elacestrant with everolimus works for the treatment of estrogen receptor (ER) positive endometrial cancer that has come back after a period of improvement (recurrent), that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Estrogen can cause the growth of cancer cells. Elacestrant lowers the amount of estrogen made by the body. This may help stop the growth of cancer cells that need estrogen to grow. Everolimus is in a class of medications called kinase inhibitors. It is also a type of angiogenesis inhibitor. Everolimus works by stopping cancer cells from reproducing and by decreasing blood supply to the cancer cells. Giving elacestrant with everolimus may be effective for treating patients with recurrent, advanced or metastatic ER positive endometrial cancer.",[168,169,170,171,172],"Advanced Endometrial Carcinoma","Metastatic Endometrial Carcinoma","Recurrent Endometrial Carcinoma","Stage III Endometrial Cancer","Stage IV Endometrial Cancer","2026-06-05",{"date":175,"type":33},"2026-06-09",{"date":177,"type":22},"2026-12-18",{"date":179,"type":22},"2029-12-18",{"name":39,"class":40},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":201,"leadSponsor":203,"locationsCount":41},"100638931","rad-onc-freedom-oncology-pain-100638931","NCT07605546","RAD ONC FREEDOM Oncology Pain","Functional Radiosurgery for Easing or Eliminating Debilitating Oncologic Morbidity (FREEDOM)","FREEDOM","Inclusion Criteria:\n\n1. Male or female ≥ 18 years of age on day of SRS treatment.\n2. Documentation of insufficiently controlled mixed, complex cancer pain based on Brief Pain Inventory (BPI) \\>8\u002F10 despite optimization of opioid regimen\n3. Not eligible for or willing to undergo further pain-relieving interventions\n4. Written informed consent (and assent when applicable) obtained from patient or patient's legal representative and ability for patient to comply with the study requirements and agree to undergo the study's SRS treatment plan.\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.\n2. Claustrophobia or inability to life flat\n3. Inability to undergo routine imaging studies\n4. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n5. Current history of intracranial malignancy or brain metastasis\n6. Any prior intracranial irradiation\n7. Previous history of craniotomy, deep brain stimulation (DBS) or laser interstitial themal therapy (LITT).\n8. Presence of intracranial hardware such as leads for DBS or any other material that may interfere with safe treatment.\n9. Any comorbidity or condition which would limit full compliance with the protocol",{"count":190,"type":22},19,[25],"The investigators propose to conduct a study in medically refractory cancer pain patients utilizing radiosurgery to ablate the pituitary hypophysis, as well as neuromodulate the centromedian and parafascicular complexes within the thalami - the so-called triple target. This involves treating the pituitary hypophysis and thalamus to a dose of 90 Gy. These patients will have previously failed to achieve adequate pain control with opioid pain regimens and interventional approaches. The trial will involve a multidisciplinary approach involving radiation oncology, neurosurgery, palliative care, and medical oncology colleagues across UCLA.",[194],"Cancer Pain",[196],"reduction","2026-06-03",{"date":199,"type":33},"2026-06-04",{"date":173,"type":22},{"date":202,"type":22},"2029-06-01",{"name":39,"class":40},{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":17,"minAge":211,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":41},"100549636","phase-2-study-of-magnetic-resonance-image-and-computed-tomography-guided-stereotactic-body-radiation-therapy-for-abdominopelvic-sarcomas-mars-trial-100549636","NCT06436612","Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)","Phase II Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)","Inclusion Criteria:\n\n* Histologically confirmed sarcoma\n* Primary or recurrent disease involving the abdomen or pelvis\n* Resectable primary lesion\n* Age ≥ 12 years old\n* Karnofsky performance status (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG) 0-2\n* If a woman is of childbearing potential, a negative serum or urine pregnancy test must be documented\n\nExclusion Criteria:\n\n* Active treatment of a separate malignancy\n* History of prior irradiation to the area targeted for treatment","12 Years",{"count":213,"type":22},20,[53],"Recent advances in radiation treatment have allowed for higher doses per treatment to be delivered safely. This study plans to use an MRI-guided linear accelerator to deliver the radiation treatment to ensure that the radiation dose is administered to the cancerous tumor, not the vital body organs.\n\nPotential participants with a sarcoma diagnosis will be referred to Radiation Oncology during this study. If the participant is interested in participating in this study, s\u002Fhe receives radiation treatment daily for 5 consecutive days except for weekends and holidays. Within 12 weeks of completing the radiation therapy, the participant will have the primary tumor surgically removed. The radiation oncology team will follow the patients for 5 years after completing radiation therapy.",[217],"Abdominopelvic Sarcomas",{"date":173,"type":33},{"date":220,"type":33},"2024-05-30",{"date":222,"type":22},"2028-05-26",{"name":39,"class":40},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":41},"100637571","phase-1-ab801-in-combination-with-chemotherapy-and-immunotherapy-for-the-treatment-of-patients-with-borderline-resectable-locally-advanced-or-metastatic-cholangiocarcinoma-or-pancreatic-cancer-100637571","NCT07619313","AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer","A Phase 1\u002F1b Trial of AB801 in Combination With Chemotherapy and PD-1\u002FPD-L1 Blockade in Patients With Cholangiocarcinoma or Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age and willing and able to provide informed consent\n* Previously untreated cytologically or histologically confirmed, at least one measurable lesion via Response Evaluation Criteria in Solid Tumors (RECIST 1.1) of cholangiocarcinoma or pancreatic adenocarcinoma meeting following criteria:\n\n  * Cholangiocarcinoma\n\n    * Borderline resectable\u002Flocally advanced cholangiocarcinoma: to be defined as unresectable disease on evaluation by a hepatobiliary multi-disciplinary tumor board\u002Fsurgeon based on tumor size\u002Flocation, vascular involvement, and absence of extrahepatic metastasis.\n    * Metastatic cholangiocarcinoma: Patients with metastatic cholangiocarcinoma patient who have not received prior systemic therapy\n  * Pancreatic adenocarcinoma\n\n    * Borderline resectable pancreatic adenocarcinoma: There are multiple definitions of borderline resectable pancreatic ductal adenocarcinoma (PDAC). For the purposes of this study, borderline resectable disease will be identified per the National Comprehensive Cancer Network (NCCN) criteria. Per this definition, borderline resectable PDAC is defined as the presence of any one or more of the following on CT:\n\n      * An interface between the tumor and superior mesenteric artery (SMA) or celiac axis (CA) measuring \\\u003C 180º of the circumference of the vessel wall.\n      * An interface between the tumor with the common hepatic artery without extension into the celiac axis or hepatic artery bifurcation allowing for safe and complete resection and reconstruction.\n      * An interface between the primary tumor and the superior mesenteric vein or portal vein (SMV-PV) measuring ≥ 180° of the circumference of the vessel wall\n      * Short-segment occlusion of the SMV-PV with normal vein above and below the level of obstruction that is amenable to resection and venous reconstruction\n      * An interface between the primary tumor and the inferior vena cava (IVC)\n    * Locally advanced pancreatic adenocarcinoma: Multiple guidelines defining locally advanced PDAC have been developed. For the purposes of this study, locally advanced PDAC cases will be identified per the definition developed by the NCCN. Per this definition, locally advanced PDAC is defined as presence of any one or more of the following on CT:\n\n      * Interface between the tumor and SMA or CV measuring \\> 180º of the circumference of the vessel wall or solid tumor contact with the CA and aortic involvement.\n      * Occlusion of the SMV-PV that is not amenable to resection and venous reconstruction\n  * Metastatic pancreatic adenocarcinoma: Patients with metastatic pancreatic adenocarcinoma who have not received prior systemic therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Absolute neutrophil count (ANC) ≥ 1.5x10\\^9\u002FL\n* Platelets ≥ 100x10\\^9\u002FL\n* Hemoglobin ≥ 9 g\u002FdL\n* Creatinine clearance (Ccr) ≥ 50 mL\u002Fmin (as calculated by Modified Cockcroft-Gault formula)\n* Serum total bilirubin ≤ 2x upper limit of normal (ULN) or \\\u003C 3x ULN if Gilbert's syndrome\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase \\[SGPT\\]) ≤ 2.5 X ULN; \\\u003C 5x ULN in patients with liver metastases\n* Women with no childbearing potential because of surgery or who are at least 1 year postmenopausal (ie, 12 months post last menstrual period) or with menopause confirmed by follicle-stimulating hormone testing, OR\n* Women of childbearing potential (defined as any female who has experienced menarche and is not permanently sterile or post-menopausal) must use an effective nonhormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap \\[diaphragm or cervical or vault caps\\] with spermicidal foam or gel or film or cream or suppository; or vasectomized male partner if he is the sole partner of that participant) or practice true abstinence for the duration of the study and for up to 14 months after the last systemic treatment\n* Male participants must use an effective method of contraception (condom or occlusive cap \\[diaphragm or cervical or vault caps\\] with spermicidal foam or gel or film or cream or suppository; or vasectomy) or practice true abstinence as defined throughout the study and for up to 11 months after the systemic treatment\n* Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed topical corticosteroids (doses \\> 10 mg\u002Fday prednisone or equivalent) must be discontinued at least 2 weeks (14 days) before study treatment administration. Physiologic doses of corticosteroids (≤ 10 mg\u002Fday of prednisone or its equivalent) or short pulses of corticosteroids (≤ 3 days) may be permitted\n* Products with known potential to prolong the corrected QT (QTc) interval should be avoided when possible. When able will replace non-prolonging QTc acting drug when available and if medically necessary\n* Major surgery as defined by the Investigator must be completed at least 4 weeks before study treatment administration. Participants should have recovered from the surgical procedure prior to the first dose being administered\n* Adequate baseline tumor tissue sample for correlative studies\n\nExclusion Criteria:\n\n* Previous treatment with any of planned study drugs in cholangiocarcinoma, though patients with one cycle of gemcitabine\u002Fcisplatin\u002Fdurvalumab will be considered eligible\n* Previous treatment with any of planned study drugs in pancreatic adenocarcinoma, though patients with one cycle of FOLFIRINOX will be considered eligible\n* Peripheral neuropathy \\> grade 2\n* Known status of HIV which is not well-controlled (CD4 \\\u003C 300) at the time of study eligibility. Patients with controlled and treated HIV\u002Fhepatitis C virus (HCV) and an undetectable viral load are allowed\n* Untreated hepatitis B infection; Patient has known active hepatitis B virus (HBV) or hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection (testing is not mandatory, unless known active or known history of infection or required by local regulation):\n\n  * Participants with resolved or treated HCV (ie, HCV antibody positive but undetectable HCV ribonucleic acid \\[RNA\\]) will not be excluded from this study\n* Underlying medical conditions that, in the Investigator's opinion, will make the administration of investigational product (IP)(s) hazardous, including but not limited to:\n\n  * Interstitial lung disease, including history of interstitial lung disease or non-infectious pneumonitis\n  * Active viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of the initiation of the IP,\n  * Active infection or antibiotics within 48 hours prior to study screening;\n  * A condition or unresolved adverse event (AE) from a prior investigational drug that may obscure the interpretation of toxicity determination or AEs,\n  * History of prior solid-organ transplantation\n* Any history of malignancy less than 5 years prior to the time of study eligibility (Patients with history of skin cancers excluding melanoma and cancers with a very low risk of recurrence i.e., low grade prostate cancer, thyroid cancer and low risk cervical cancer will be eligible for participation)\n* Serious medical comorbidities such as New York Heart Association Class III\u002FIV cardiac disease, uncontrolled cardiac arrhythmias, myocardial infarction over the past 12 months\n* Known family history or personal history of long QTc syndrome or previous drug-induced QTc prolongation of at least grade 3 (QTc \\> 500 ms)\n* Screening 12-lead electrocardiogram (ECG), in triplicate, with a measurable QTc interval of \\> 450ms\n* Known, existing uncontrolled coagulopathy. Patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation are eligible IF: they are appropriately anticoagulated and have not had a grade 2 or greater bleeding episode in the 3 weeks before day 1\n* Known pregnancy, nursing women or positive pregnancy test. Requirement for women of childbearing potential (WOCBP): Negative serum pregnancy test at screening and serum or urine prior to dosing on cycle 1 day 1, within 24 hours prior to the start of treatment (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[HCG\\]). WOCBP must also have a negative serum or urine pregnancy test every 3 weeks, within 24 hours prior to the start of treatment\n* Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the investigator\n* History of trauma or major surgery within 28 days prior to the first dose of IP\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Any active or documented history of autoimmune disease, including but not limited to inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of study treatment, except for the following:\n\n  * Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders such as vitiligo, or alopecia not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger.\n  * Endocrinopathies where the participant is stable on hormone replacement therapy\n  * History of Hashimoto syndrome within 3 years of the first of study treatment that resolved to hypothyroidism alone",{"count":232,"type":22},46,[52],"This phase I trial tests the safety, side effects, best dose and effectiveness of AB801 in combination with chemotherapy and immunotherapy in treating patients with cholangiocarcinoma or pancreatic adenocarcinoma that may be removed by surgery (borderline resectable), that has spread to nearby tissue or lymph nodes (locally advanced), or that has spread from where it first started (primary site) to other places in the body (metastatic). AB801 is a drug designed to block a protein called AXL. AXL is found on the surface of certain cancer cells and plays an important role in helping tumors grow, spread to other parts of the body, and avoid the immune system. It is thought to contribute to resistance against common cancer treatments such as chemotherapy, radiation and immunotherapy. In many cancers, including cholangiocarcinoma and pancreatic adenocarcinoma, AXL is overactive and associated with worse outcomes. AB801 inhibits AXL which may make cancer cells more sensitive to chemotherapy and allow immune cells to better recognize and attack the tumor. Chemotherapy drugs, such as gemcitabine, cisplatin, oxaliplatin, irinotecan, leucovrin and fluorouracil, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and zimberelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving AB801 in combination with chemotherapy and immunotherapy may better treat patients with borderline resectable, locally advanced or metastatic cholangiocarcinoma or pancreatic adenocarcinoma.",[236,237,238,239,240,241,242,243],"Borderline Resectable Pancreatic Ductal Adenocarcinoma","Locally Advanced Cholangiocarcinoma","Locally Advanced Pancreatic Adenocarcinoma","Metastatic Cholangiocarcinoma","Metastatic Pancreatic Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","2026-06-02",{"date":199,"type":33},{"date":247,"type":22},"2026-06-01",{"date":249,"type":22},"2028-06-01",{"name":39,"class":40},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":270},"100591411","phase-2-ivonescimab-for-the-treatment-of-thymic-cancer-100591411","NCT06980077","Ivonescimab for the Treatment of Thymic Cancer","UCLA L-11: A Phase II Trial of Ivonescimab for Previously Treated Thymic Carcinoma","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age and willing and able to provide informed consent\n* Cytologically or histologically confirmed thymic carcinoma, which is incurable\n* Received prior systemic therapy for thymic carcinoma, or is ineligible for or refuses other therapies\n* Measurable disease, as per RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL\n* Platelets ≥ 100 × 10\\^9\u002FL\n* Hemoglobin ≥ 9 g\u002FdL or ≥ 5.6 mmol\u002FL\n* Serum creatinine ≤ 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (CrCl) ≥ 50 mL\u002Fmin (glomerular filtration rate \\[GFR\\] can also be used in place of creatinine or CrCl)\n\n  * Estimated glomerular filtration rate (eGFR) value ≥ 50 mL\u002Fmin for participants with creatinine levels \\> 1.5 x institutional ULN\n  * Creatinine clearance may be calculated using the Cockcroft-Gault formula or estimated glomerular filtration rate (eGFR) may be calculated using the Modification of Diet in Renal Disease (MDRD) GFR equation\n* Urine dipstick protein ˂ 2+ OR 24 hour urine protein quantification ˂ 1.0 g\n* Serum total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) ≤ 2.5 x ULN OR ≤ 5 x ULN for participants with liver metastases\n* Albumin ≥ 2.5 g\u002FdL\n* International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN unless participant is receiving anticoagulant therapy, and then only as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants\n* Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless participant is receiving anticoagulant therapy, and then only as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n* Female participants of childbearing potential must have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the participant to be eligible. Female participants must agree to use a highly effective method of contraception from the beginning of screening until 120 days after the last dose of the ivonescimab, or be of non-childbearing potential. Non-childbearing potential is defined as follows (by other than medical reasons):\n\n  * ≥ 45 years of age and has not had menses for \\> 2 years,\n  * Participants who have been amenorrhoeic for \\\u003C 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation, or\n  * Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation\n* Unsterilized male patients having sex with a female partner of childbearing potential, or a pregnant or breastfeeding partner must agree to use barrier contraception (male condom) for the duration of the treatment period until 120 days after the last dose of ivonescimab. Male patients with female partners of childbearing potential must have the female partner agree to use at least 1 form of highly effective contraception for the duration of the treatment period until 120 days after the last dose of ivonescimab\n* Male and female participants must agree not to donate sperm or eggs, respectively, from the first study-drug treatment through 120 days after the last study drug treatment\n* Female participants must agree to not breastfeed during the study or for 120 days after the last dose of study treatment\n\nExclusion Criteria:\n\n* Prior treatment with an immune checkpoint inhibitor targeted PD-1 or PD-L1. Prior treatment with VEGF inhibitor is allowed\n* Concurrent enrollment in another clinical study, unless enrolled only in the follow-up period or an observational study\n* Any chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment in the prior 3 weeks or within 5 half-lives of the medication, whichever is shorter. Concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable\n* Thoracic radiation of ≥ 30 Gy within 3 months. Other radiation within 3 weeks with the following exceptions: (a) Stereotactic, palliative radiation for bone metastases is acceptable without a washout; (b) Stereotactic brain radiation for asymptomatic brain metastases is acceptable with a 7 day washout\n* Use of any investigational anticancer therapy received within 21 days prior to the first dose of study drug\n* Has not recovered (recovery is defined as National Cancer Institute \\[NCI\\] Common Terminology Criteria for Adverse Events \\[CTCAE version (v)5.0\\] grade ≤ 1) from the acute toxicities of previous therapy, except treatment-related alopecia, sensory neuropathy, or laboratory abnormalities otherwise meeting the inclusion requirements stated in the inclusion criterion. Other grade 2 or less toxicities not constituting a safety risk based on the investigator's judgment are acceptable\n* The patient has a known allergy\u002Fhistory of hypersensitivity reaction to any of the treatment components or any other contraindication to one of the administered treatments\n* Active autoimmune condition currently requiring systemic immune suppressive therapy\n* Positive paraneoplastic serologies, including binding, blocking and modulating antibodies to acetylcholine receptor (AChR)\n\n  * If known muscle-specific kinase (MuSK) antibodies positive then excluded, otherwise additional testing not required\n* Major surgical procedures or serious trauma within 4 weeks prior to randomization, or plans for major surgical procedures within 4 weeks after the first dose (as determined by the investigator). Minor local procedures (excluding central venous catheterization and port implantation) within 3 days prior to randomization\n* Poorly controlled hypertension with repeated systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy\n* Presence of angina or active cardiac ischemia, uncontrolled congestive heart failure of current ≥ class III as defined by the New York Heart Association, or unstable cardiac arrhythmia (e.g., clinically stable atrial fibrillation is permitted)\n* The patient has experienced myocardial infarction within 6 months prior to study enrollment\n* History of arterial or venous thrombosis or thromboembolism within 6 months prior to study enrollment. Patients with a history of venous thromboembolism beyond 6 months prior to study enrollment can be enrolled if they are appropriately anticoagulated\n* Imaging during the screening period shows that the tumor surrounds important blood vessels or has obvious necrosis and\u002For cavitation, and the investigator determines that entering the study is a bleeding or fistula risk. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is permitted\n* The patient has any ongoing or active infection requiring the use of parenteral anti-microbial agents, or grade \\> 2 by NCI CTCAE (v5.0) within 14 days prior to enrollment. Patient with a history of HIV with an undetectable viral load and cluster of differentiation 4 (CD4) count over 200 are eligible. Patients with a history of hepatitis B or hepatitis C, an undetectable viral load, and liver function test (LFT) testing which meets criteria for the study are eligible\n* The patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 210 days after the last dose of trial treatment\n* Progressive or symptomatic brain metastases. Brain metastases that have been radiated, are asymptomatic, and on a stable or decreasing dose of steroids are allowed. Leptomeningeal disease is excluded\n* History of another cancer within 2 years of study initiation, with the exception of fully treated cancers unlikely to affect the assessment of the study treatment safety or efficacy including early stage breast, prostate, bladder, non-melanomatous skin, thyroid, cervical, or endometrial cancer\n* History of bleeding tendencies or coagulopathy and\u002For clinically significant bleeding symptoms or risk within 4 weeks prior to randomization, including but not limited to:\n\n  * Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots)\n\n    * Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed\n  * Nasal bleeding\u002Fepistaxis (bloody nasal discharge is allowed)\n* Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable prior to randomization is not allowed. The use of full-dose anticoagulants is permitted as long as the international normalized ratio (INR) or activated partial thromboplastin time (aPTT) is within therapeutic limits according to the medical standard of the enrolling institution. History of esophageal gastric varices, severe ulcers, wounds that do not heal, abdominal fistula, intra-abdominal abscesses, or acute gastrointestinal bleeding within 6 months before randomization\n* History of perforation of the gastrointestinal tract and\u002For fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to randomization\n* Active autoimmune or lung disease requiring systemic therapy (eg, with disease modifying drugs, prednisone \\> 10 mg daily or equivalent, immunosuppressant therapy) within 2 years prior to randomization, however the following will be allowed:\n\n  * Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is permitted.\n  * Intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections is permitted\n* Has pre-existing peripheral neuropathy that is ≥ grade 2 by CTCAE version 5\n* Uncontrolled pleural effusions, pericardial effusions, or ascites that is clinically symptomatic\n\n  * Patients managed with indwelling catheters (eg, PleurX) are allowed\n* History of non-infectious pneumonia requiring systemic corticosteroids, or current interstitial lung disease\n* Active or prior history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)\n* Known history of human immunodeficiency virus (HIV) whose viral load is not controlled\n* Current use of systemic corticosteroids (\\> 10 mg daily prednisone or equivalent)\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation\n* Live vaccine or live attenuated vaccine within 4 weeks prior to planned randomization, or if scheduled to receive a live vaccine or live attenuated vaccine during the study period. Inactivated vaccines are permitted\n* Participants must not be considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent\n* Patient unwilling or unable to comply with the protocol\n* Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product or interpretation of subject safety or study results",{"count":7,"type":22},[53],"This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.",[262],"Thymus Carcinoma","2026-05-28",{"date":247,"type":33},{"date":266,"type":33},"2025-07-15",{"date":268,"type":22},"2028-06-17",{"name":39,"class":40},5,{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":41},"100640816","stage-mtc-trial-thyroid-lobectomy-with-ipsilateral-central-neck-dissection-100640816","NCT07612293","STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection","STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection for the Treatment of Sporadic Medullary Thyroid Cancer, STAGE-MTC Trial","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age at time of diagnosis\n* Documentation of a medullary thyroid cancer diagnosis as evidenced by:\n\n  * Thyroid fine needle aspiration biopsy with cytologist consistent with medullary thyroid cancer\n  * Indeterminate cytology from thyroid fine needle aspiration with elevated serum calcitonin OR thyroid molecular testing consistent with medullary thyroid cancer\n* Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study\n* Appropriate candidate for thyroid lobectomy and\u002For total thyroidectomy\n\nExclusion Criteria:\n\n* Indication for total thyroidectomy unrelated to medullary thyroid cancer:\n\n  * Graves' disease\n  * Symptomatic multinodular goiter\n  * Contralateral symptomatic benign nodules\n* Ultrasound findings consistent with:\n\n  * Cervical lymphadenopathy involving lateral neck or contralateral central neck\n  * Suspicious thyroid nodules \\> 1 cm that are Thyroid Imaging Reporting and Data Systems 2 (TIRADS2) or higher without fine needle aspiration (FNA)\n\n    * Pure cystic and spongiform nodules do not require FNA\n    * Patients with nodules that meet criteria above can elect to undergo FNA, and may enroll in study if benign cytology is noted\n* Identification of germline RET mutation on preoperative genetic testing",{"count":279,"type":22},100,[25],"This clinical trial studies how well thyroid lobectomy with ipsilateral central neck dissection works to treat medullary thyroid cancer (MTC) in patients without a germline RET mutation (sporadic). Currently, sporadic and germline RET (rearranged during transfection) mutation positive MTCs that are limited to the thyroid are managed in the same way, complete surgical removal of the entire thyroid gland (total thyroidectomy) with surgical removal of lymph nodes and other tissues on both sides of the neck (bilateral central neck dissection). Total thyroidectomy and bilateral central neck dissection carry a high risk of complications, and total thyroidectomy requires patients to take lifelong thyroid hormone replacement therapy, which can impact quality of life. Research has shown that patients with sporadic MTC do not have a high risk of developing MTC in the remaining normal thyroid tissue and that they may be able to be managed differently than patients with germline RET mutations. Thyroid lobectomy with ipsilateral central neck dissection is a surgical procedure which removes only the lobe of the thyroid gland that is affected by cancer as well as the lymph nodes and other tissues from the affected side of the neck. Thyroid lobectomy with ipsilateral central neck dissection may be a safer, more tolerable, and\u002For more effective way to treat sporadic MTC.",[283],"Thyroid Gland Medullary Carcinoma","2026-05-27",{"date":263,"type":33},{"date":287,"type":22},"2026-09-02",{"date":289,"type":22},"2032-04-21",{"name":39,"class":40},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":138,"minAge":49,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":41},"100421236","integrating-quantitative-mri-and-artificial-intelligence-to-improve-prostate-cancer-classification-100421236","NCT04765150","Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification","Inclusion Criteria:\n\n* Male patients 18 years of age and older\n* Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer\n* Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA)\n* Ability to provide consent\n\nExclusion Criteria:\n\n* Contraindications to MRI (e.g., cardiac devices, prosthetic valves, severe claustrophobia)\n* Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent\n* Prior radiotherapy",{"count":298,"type":22},275,"OBSERVATIONAL","This study evaluates how new magnetic resonance imaging (MRI) and artificial intelligence techniques improve the image quality and quantitative information for future prostate MRI exams in patients with suspicious of confirmed prostate cancer. The MRI and artificial intelligence techniques developed in this study may improve the accuracy in diagnosing prostate cancer in the future using less invasive techniques than what is currently used.",[302],"Prostate Carcinoma","2026-05-21",{"date":305,"type":33},"2026-05-26",{"date":307,"type":33},"2021-04-01",{"date":309,"type":22},"2027-06-01",{"name":39,"class":40},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":138,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":41},"100129161","active-surveillance-for-cancer-of-the-prostate-ascap-100129161","NCT00949819","Active Surveillance for Cancer of the Prostate (ASCaP)","The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.","ASCaP","Inclusion Criteria:\n\n1. Histologically confirmed adenocarcinoma of the prostate.\n2. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.\n3. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).\n4. Patient has elected Active Surveillance as preferred management plan for prostate cancer.\n5. Patient consent has been obtained according to local Institutional Review Board .\n6. Patient is accessible and compliant for follow-up.\n\nExclusion Criteria:\n\n1. Unwillingness or inability to undergo serial prostate biopsy.\n2. Overall life expectancy less than 2 years\n3. Advanced prostate cancer","30 Years","85 Years",{"count":322,"type":22},462,"Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.",[325],"Prostate Cancer",[325,327,328,329],"Low risk","Gleason 6","Active surveillance",{"date":305,"type":33},{"date":332,"type":33},"2009-07-04",{"date":334,"type":22},"2028-12",{"name":39,"class":40},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":138,"minAge":343,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":41},"100628996","focal-radiation-therapy-hdr-brachytherapy-for-the-treatment-of-prostate-cancer-100628996","NCT07468903","Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer","Phase II Trial of Focal Radiation Therapy in Patients With Prostate Cancer","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of prostate adenocarcinoma within 90 days prior to registration via systematic biopsy\n* Multiparametric MRI (mp-MRI) confirmed lesion(s)\n* No distant or locally advanced disease on standard staging exams as indicated\n\n  * Bone scan and abdominopelvic computed tomography (CT)\u002FMRI OR\n  * PSMA PET\n* Eastern Cooperative Oncology Group (ECOG)\u002FZubrod performance status 0\u002F1 within 60 days prior to enrollment\n* Age ≥ 40\n\nExclusion Criteria:\n\n* Radiographic nodal or distant metastatic disease\n* Lesion(s) comprising \\> 40% of total prostate volume\n* Prior radiotherapy to the pelvis\n* Gleason score \\> 6 disease outside intended gross target volume (GTV)\u002Ftarget region(s)","40 Years",{"count":345,"type":22},45,[25],"This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer. Prostate cancer is the most diagnosed cancer in men and there are many treatments available, including surgery and radiation therapy. Although surgery and radiation therapy improve survival urinary and sexual function can be significantly affected and can be long lasting. HDR-BT, a type of focal radiation therapy also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving HDR-BT may be effective in providing local control while reducing side effects in patients with prostate cancer.",[349,350,351],"Prostate Adenocarcinoma","Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8","Stage II Prostate Cancer AJCC v8","2026-05-19",{"date":354,"type":33},"2026-05-22",{"date":356,"type":33},"2026-05-11",{"date":358,"type":22},"2032-05-11",{"name":39,"class":40},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":41},"100492136","phase-1-zimberelimab-and-quemliclustat-in-combination-with-chemotherapy-for-the-treatment-of-patients-with-borderline-resectable-and-locally-advanced-pancreatic-adenocarcinoma-100492136","NCT05688215","Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","A Pilot Study of Zimberelimab and Quemliclustat Combination With Chemotherapy in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Male or female \\>= 18 years of age and willing and able to provide informed consent\n* Previously untreated cytologically or histologically confirmed pancreatic adenocarcinoma with one of the following:\n\n  * Borderline resectable disease. There are multiple definitions of borderline resectable PDAC including the MD Anderson definition and the criteria developed during the Consensus Conference sponsored by the American Hepato-Pancreato-Biliary Association, Society of Surgical Oncology, and Society for Surgery of the Alimentary Tract. Borderline resectable PDAC cases will be identified per the definition developed in the currently running inter-group pilot trial for borderline resectable pancreatic cancer (NCT01821612). Per this trial, borderline resectable PDAC is defined as the presence of any one or more of the following on CT;\n\n    * An interface between the primary tumor and the superior mesenteric vein or portal vein (SMV-PV) measuring \\>= 180 degrees of the circumference of the vessel wall\n    * Short-segment occlusion of the SMV-PV with normal vein above and below the level of obstruction that is amenable to resection and venous reconstruction\n    * Short segment interface (of any degree) between tumor and hepatic artery with normal artery proximal and distal to the interface that is amenable to resection and reconstruction\n    * An interface between the tumor and SMA measuring \\\u003C 180 degrees of the circumference of the vessel wall\n  * Locally advanced disease. Multiple guidelines defining locally advanced PDAC have been developed, including the MD Anderson definition, the National Comprehensive Cancer Network (NCCN) definition, as well as the criteria developed during the Consensus Conference sponsored by the American Hepato-Pancreato-Biliary Association, Society of Surgical Oncology, and Society for Surgery of the Alimentary Tract. Locally advanced PDAC cases will be identified per the definition developed by the Alliance for Clinical Trials in Oncology. Per this definition, locally advanced PDAC is defined as presence of any one or more of the following on CT;\n\n    * Occlusion of the SMV-PV that is not amenable to resection and venous reconstruction\n    * Interface between tumor and hepatic artery that is not amenable to resection and reconstruction\n    * Interface between the tumor and SMA measuring \\> 180 degrees of the circumference of the vessel wall\n    * Interface between the tumor and celiac axis measuring \\> 180 degrees of the circumference of the vessel wall\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\u002FL\n* Platelets \\>= 100 x 10\\^9\u002FL\n* Hemoglobin \\>= 9 g\u002FdL\n* Serum creatinine (sCr) =\\\u003C 1.5 x upper limit of normal (ULN) or Creatinine clearance (Ccr) \\>= 40 mL\u002Fmin (as calculated by Modified Cockcroft-Gault formula)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (AST\u002F\\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 2.5 X ULN\n* Women with no childbearing potential because of surgery or who are at least 1 year postmenopausal (ie, 12 months post last menstrual period) or with menopause confirmed by follicle-stimulating hormone testing\n* Women of childbearing potential must use an effective nonhormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap \\[diaphragm or cervical or vault caps\\] with spermicidal foam or gel or film or cream or suppository; or vasectomized male partner if he is the sole partner of that participant) for the duration of the study and for up to 6 months after the last dose of zimberelimab or quemliclustat\n* Male participants must use an effective method of contraception (condom or occlusive cap \\[diaphragm or cervical or vault caps\\] with spermicidal foam or gel or film or cream or suppository, or vasectomy) throughout the study and for up to 6 months after the last dose of zimberelimab or quemliclustat\n* Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed topical corticosteroids (doses \\> 10 mg\u002Fday prednisone or equivalent) must be discontinued at least 2 weeks (14 days) before study treatment administration. Physiologic doses of corticosteroids (=\\\u003C 10 mg\u002Fday of prednisone or its equivalent) or short pulses of corticosteroids (=\\\u003C 3 days) may be permitted\n* Prior surgery that required general anesthesia or other major surgery as defined by the Investigator must be completed at least 4 weeks before study treatment administration. Surgery requiring regional\u002Fepidural anesthesia must be completed at least 72 hours before study treatment administration. Participants should have recovered from the surgical procedure prior to the first dose being administered\n\nExclusion Criteria:\n\n* Recurrent or metastatic pancreatic adenocarcinoma\n* Peripheral neuropathy \\> grade 2\n* Known status of human immunodeficiency virus (HIV) which is not well-controlled (CD4 \\\u003C300) at the time of study eligibility. Patients with controlled and treated HIV\u002FHepatitis C virus (HCV) and an undetectable viral load are allowed\n* Untreated Hepatitis B infection: Patient has known active hepatitis B virus (HBV) or hepatitis C virus (HCV), or Human immunodeficiency virus (HIV) infection (testing is not mandatory, unless required by local regulation)\n\n  * Participants with resolved or treated HCV (ie, HCV antibody positive but undetectable HCV ribonucleic acid \\[RNA\\]) will not be excluded from this study\n* Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational products (IPs) hazardous, including but not limited to:\n\n  * Interstitial lung disease, including history of interstitial lung disease or non-infectious pneumonitis (lymphangitic spread of non-small cell lung cancer (NSCLC) is not disqualifying)\n  * Active viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of the initiation of the IP\n  * Active infection or antibiotics within 48 hours prior to study screening\n  * Clinically significant cardiovascular disease\n  * A condition or unresolved adverse event (AE) from a prior investigational drug that may obscure the interpretation of toxicity determination or AEs\n  * History of prior solid-organ transplantation\n* Currently active second primary malignancy or history of malignancy less than 5 years prior to the time of study eligibility (Patients with history of skin cancers excluding melanoma will be eligible for participation)\n* Serious medical comorbidities such as New York Heart Association Class III\u002FIV cardiac disease, uncontrolled cardiac arrhythmias, myocardial infarction over the past 12 months\n* Known, existing uncontrolled coagulopathy. Patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation are eligible IF: they are appropriately anticoagulated and have not had a Grade 2 or greater bleeding episode in the 3 weeks before Day 1\n* Known pregnancy, nursing women or positive pregnancy test. Requirement for women of child-bearing potential (WOCBP): Negative serum pregnancy test at screening and prior to dosing on Cycle 1 Day 1, within 24 hours prior to the start of treatment (minimum sensitivity 25 IU\u002FL or equivalent units of HCG). WOCBP must also have a negative serum or urine pregnancy test every 4 weeks, within 24 hours prior to the start of treatment\n* Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the investigator\n* History of trauma or major surgery within 28 days prior to the first dose of IP\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Any active or documented history of autoimmune disease, including but not limited to inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of study treatment, except for the following:\n\n  * Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders such as vitiligo, or alopecia not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger\n  * Endocrinopathies where the participant is stable on hormone replacement therapy\n  * History of Hashimoto syndrome within 3 years of the first of study treatment that resolved to hypothyroidism alone\n* History of a syndrome that required systemic steroids or immunosuppressive medications, except for vitiligo or resolved childhood asthma\u002Fatopy. Participants with asthma who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study",{"count":368,"type":22},56,[52,53],"This phase I\u002FII study tests how well zimberelimab and quemliclustat work in combination with chemotherapy (mFOLFIRINOX) in treating patients pancreatic adenocarcinoma that may or may not be able to be removed by surgery (borderline resectable) or that has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as zimberelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Quemliclustat acts as a blocker for adenosine. Adenosine is a chemical produced in the body that can lead to a decrease in the immune system's response towards cancer. Quemliclustat has the potential to decrease the amount of adenosine, allowing the immune system to recognize and act against the cancer. Chemotherapy drugs, such as oxaliplatin, irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy in combination with zimberelimab and quemliclustat may kill more cancer cells than chemotherapy alone.",[372,373],"Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Ductal Adenocarcinoma",{"date":354,"type":33},{"date":376,"type":33},"2023-03-07",{"date":378,"type":22},"2027-03-02",{"name":39,"class":40},{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":390,"conditions":391,"keywords":394,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":270},"100576718","phase-2-tarlatamab-in-advanced-delta-like-3-dll3-expressing-tumors-including-neuroendocrine-neoplasms-100576718","NCT06788938","Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms","Tarlatamab in Advanced DLL3-Expressing Tumors Including Neuroendocrine Neoplasms","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n1. Participant has provided informed consent prior to initiation of any study specific activities\u002Fprocedures.\n2. Male or female ≥ 18 years of age and willing and able to provide informed consent.\n3. Histologically or cytologically confirmed malignancy other than de novo (i.e., non-transformed) SCLC or NEPC. Must be stage IV (metastatic); participants with stage III disease are eligible provided that they are not candidates for surgery and\u002For radiotherapy with curative intent. Acceptable tumor types include the following:\n\n   * Low and intermediate grade neuroendocrine carcinoma (including carcinoid and atypical carcinoid)\n   * Gastroenteropancreatic NEN\n   * Large cell neuroendocrine carcinoma\n   * SCLC transformed from previously-treated NSCLC\n   * Extrapulmonary small cell carcinoma, with the exception of NEPC\n   * Any other tumor type that meets staging and DLL3 positivity criteria\n4. Positive DLL3 expression by immunohistochemistry on tumor biopsy.\n\n   • Positive DLL3 expression, for purposes of this study, defined as at least 25% for participants enrolling into Stage 1 or 1% for participants enrolling into Stage 2.\n5. Participants must have progressed on or following at least one line of therapy, if a standard of care therapy exists for the tumor type.\n6. Measurable disease, as per RECIST 1.1\n7. ECOG performance status of 0-1.\n8. Adequate organ function as defined in Table 3 below. System Laboratory Value Hematological Absolute neutrophil count (ANC) ≥ 1.0 x 109\u002FL Platelets ≥ 100 x 109\u002FL Hemoglobin ≥ 9 g\u002FdL Renal Estimated glomerular filtration rate (eGFR) based on Modification of Diet in Renal Disease (MDRD) ≥ 30 mL\u002Fmin\u002F1.73 m2 Hepatic Serum total bilirubin ≤ 1.5 x ULN, with the exception of participants with Gilbert's disease AST (SGOT) and ALT (SGPT) ≤ 3 x ULN≤ 5 x ULN for patients with liver metastasis or primary liver cancer Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT), and Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN unless participant is receiving anticoagulant therapy, and then only as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n\nExclusion Criteria:\n\nDisease Related\n\n1. Diagnosis of SCLC (with the exception of SCLC transformed from previously-treated NSCLC) or NEPC.\n2. Tumor specimen is not evaluable for DLL3 expression or tumor has DLL3 surface expression \\\u003C 1% by immunohistochemistry.\n3. Progressive or symptomatic brain metastases. Brain metastases that have been radiated, are asymptomatic, and on a stable or decreasing dose of steroids are allowed. Leptomeningeal disease is excluded.\n4. Evidence of interstitial lung disease or active, non-infectious pneumonitis. Exception: pneumonitis related to prior radiation therapy that is grade 1 and stable or improving without treatment.\n\n   Prior\u002FConcomitant Therapy\n5. Concurrent enrollment in another clinical study, unless enrolled only in the follow-up period or an observational study. Use of any investigational anticancer therapy must not have been received within 28 days prior to the first dose of study drugs.\n6. Any chemotherapy, antibody drug conjugate or immunotherapy for cancer treatment in the prior 21 days, or small molecular inhibitor in the prior 7 days.\n\n   • Stereotactic, palliative radiation for symptomatic bone metastases is acceptable without a washout.\n\n   • Stereotactic brain radiation for asymptomatic brain metastases is acceptable with a 7-day washout.\n7. Prior therapy with any selective inhibitor of the DLL3 pathway.\n8. Prior history of severe or life-threatening events from any immune-mediated therapy.\n9. Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment. Low-dose corticosteroids (prednisone ≤ 10 mg per day or equivalent is permitted)\n10. Major surgical procedures within 28 days prior to first dose of study treatment.\n11. Treatment with live virus, including live-attenuated vaccination, within 14 days prior to the first dose of study treatment. Inactive vaccines (e.g., non-live or non-replicating agent) and live viral non-replicating vaccines within 3 days prior to first dose of study treatment.\n\n    Other Medical Conditions\n12. History of other malignancy within the past 2 years, with the following exceptions:\n\n    • Malignancy treated with curative intent before enrollment, with no known active disease and felt to be at low risk for recurrence by the treating physician, after discussion with the medical monitor.\n    * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n    * Adequately treated cervical carcinoma in situ without evidence of disease.\n    * Adequately treated breast ductal carcinoma in situ without evidence of disease.\n    * Prostatic intraepithelial neoplasia without evidence of prostate cancer.\n    * Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.\n13. History of myocardial infarction and\u002For symptomatic congestive heart failure (New York Heart Association, class II) within 6 months prior to first dose of study treatment.\n14. History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 6 months prior to first dose of study treatment.\n15. Human immunodeficiency virus (HIV) infection.\n\n    • Participants with HIV infection on antiviral therapy and undetectable viral load are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on study per local or institutional guidelines\n16. Active hepatitis C infection.\n\n    • Defined as participants with detectable hepatitis C antibody \\[HCV Ab\\] and hepatitis C virus \\[HCV\\] RNA viral load above the limit of quantification\n\n    • Participants with presence of HCV antibody (HCV Ab positive) and HCV RNA viral load below the limit of quantification (HCV RNA negative) with or without prior treatment are allowed\n17. Active hepatitis B infection. • Defined as presence of hepatitis B surface antigen \\[HBsAg-positive\\] and hepatitis B virus \\[HBV\\] DNA viral load above the limit of quantification \\[HBV DNA positive\\] • Participants with resolved HBV infection defined as absence of HBV surface antigen (HBsAg-negative) and presence of HBV core antibody (anti-HBc positive) followed by an HBV DNA viral load below the limit of quantification (HBV DNA negative) are allowed, with a requirement for regular monitoring for reactivation for the duration of treatment on the study and assessing the need for HBV prophylaxis therapy per local or institutional guidelines.\n\n    • Participants with chronic HBV infection inactive carriers state, defined as presence of HBV surface antigen (HBsAg-positive) and HBV DNA viral load below the limit of quantification (HBV DNA negative) are allowed, with a requirement for regular monitoring for reactivation for the duration of treatment on the study and assessing the need for HBV prophylaxis therapy per local or institutional guidelines.\n18. Participants with symptoms and\u002For clinical signs and\u002For radiographic signs that indicate an acute and\u002For uncontrolled active systemic infection within 7 days prior to the first dose of study treatment.\n\n    * Upon completion of antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint.\n    * Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment. Participants requiring oral antibiotics who have been afebrile \\> 24 hours, have no leukocytosis, nor clinical signs of infection are eligible. Screening for chronic infectious conditions is not required unless otherwise noted as exclusion criteria.\n\n    Other Exclusions\n19. Female participants of childbearing potential unwilling to use protocol specified method of contraception (see Section 5.7.2) during treatment and for an additional 60 days after the last dose of study treatment.\n20. Female participants who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of study treatment.\n21. Female participants planning to become pregnant or donate eggs while on study through 60 days after the last dose of study treatment.\n22. Female participants of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.\n23. Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose.\n24. Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of study treatment.\n25. Male participants unwilling to abstain from donating sperm during treatment and for an additional 60 days after the last dose of study treatment.\n26. Participant has known sensitivity to any of the products or components to be administered during dosing.\n27. Participant likely to not be available to complete all protocol-required study visits or procedures, and\u002For to comply with all required study procedures (e.g., Clinical Outcome Assessments) to the best of the participant's and investigator's knowledge.\n28. History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion.\n\n    \\-",{"count":388,"type":22},29,[53],"This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.",[392,393],"DLL3-expressing Tumors","Advanced Tumors",[395],"tumor","2026-05-14",{"date":398,"type":33},"2026-05-18",{"date":400,"type":33},"2025-03-21",{"date":402,"type":22},"2029-04-24",{"name":39,"class":40},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":23,"phases":413,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":41},"100626734","individually-tailored-supervised-remote-exercise-intervention-to-improve-physical-function-for-stage-i-iii-gastroesophageal-cancer-survivors-precise-trial-100626734","NCT07439484","Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial","A Pilot Study of an Individually Tailored, Supervised, Remotely Delivered Exercise Intervention to Improve Physical Function in Survivors of Gastroesophageal Cancer (PRECISE Study)","PRECISE","Inclusion Criteria:\n\n* Adults ≥ 18 years old at the start of study treatment\n* Diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric cancer. Histology can be adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma\n* Treated with at least one systemic therapy (chemotherapy or immunotherapy) and within 12 months of completing curative intent gastroesophageal cancer (GEC) treatment\n* Have evidence of physical function impairment, defined as a SPPB score of \\\u003C 12) at baseline\n* Ability to understand English and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients with stage I disease who underwent endoscopic resection or surgery alone without perioperative systemic therapy\n* Patients with stage IV disease or unresectable locally advanced disease taking a palliative treatment approach without a clearly defined end of treatment\n* Patients currently receiving ongoing systemic therapy for GEC or another malignancy\n* Patients who are unable to provide informed consent\n* Any other condition or pre-existing co-morbidity that would, in the Investigator's judgment, contraindicate the participation in the study due to safety concerns with study procedures\n* Currently participating in another exercise intervention research study seeking to improve functional status, alleviate frailty, muscle strength, exhaustion\u002Ffatigue, or cognitive function",{"count":213,"type":22},[25],"This clinical trial tests an individually tailored, supervised, remote exercise intervention to improve physical function for stage I-III gastroesophageal cancer survivors. Modern treatments for gastroesophageal cancer are effective at treating the cancer but are often aggressive, can be difficult for patients to tolerate, and can lead to significant debilitation and a loss of independence. Exercise is one promising intervention that could improve physical function in patients with gastroesophageal cancer after finishing systemic treatment. Home based exercise interventions in patients with cancer during and after chemotherapy can improve fatigue and function. An individually tailored, supervised, remote exercise intervention may improve physical function for stage I-III gastroesophageal cancer survivors.",[416,417,418,419,420,421,422,423,424,425,426,427],"Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8","Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage I Gastric Cancer AJCC v8","Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage II Esophageal Adenocarcinoma AJCC v8","Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage II Gastric Cancer AJCC v8","Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","2026-05-07",{"date":356,"type":33},{"date":431,"type":22},"2026-09-01",{"date":433,"type":22},"2028-09-01",{"name":39,"class":40},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":444,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":41},"100533376","phase-1-fluoxetine-for-the-modification-of-colorectal-tumor-immune-cells-before-surgery-in-patients-with-colorectal-cancer-100533376","NCT06225011","Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer","Repurposing Drugs as Immunotherapeutic Agents: Changes in Colorectal Tumor Immune Cells After Targeting Serotonin","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age at visit 1\n* Previously untreated cytologically or histologically confirmed colorectal adenocarcinoma that will not need neoadjuvant therapy\n* Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study\n* World Health Organization (WHO) Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Absolute neutrophil count (ANC) ≥ 1.5x10\\^9\u002FL\n* Platelets ≥ 100x10\\^9\u002FL\n* Hemoglobin ≥ 9 g\u002FdL\n* Serum creatinine (sCr) ≤ 1.5 x upper limit of normal (ULN)\n* Creatinine clearance (Ccr) ≥ 40 mL\u002Fmin (as calculated by Modified Cockcroft-Gault formula)\n* Serum total bilirubin ≤ 1.5 x ULN\n* Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase \\[SGOT\\]) \u002F alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \\[SGPT\\]) ≤ 2.5 x ULN\n* Baseline corrected QT (QTc) within normal limits per the Bazett formula. Any electrocardiogram (EKG) done prior to consent is acceptable for baseline QTc monitoring.\n\n  * Normal QTc ranges from 350-450 ms for adult men and from 360-460 ms for adult women\n\nExclusion Criteria:\n\n* Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the participant or the quality of the data\n* A diagnosis of metastatic colorectal adenocarcinoma\n* Individuals who have received neoadjuvant chemotherapy prior to the planned colon cancer resection\n* Individuals with absolute or relative contraindications to fluoxetine\n\n  * Baseline prolonged QTc\n  * Concurrently taking tamoxifen, pimozide, or thioridazine\n* Individuals using other SSRIs, serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), lithium or other antidepressants at time of initial biopsy\n* Currently active second primary malignancy or history of malignancy less than 5 years prior to the time of study eligibility (Patients with history of skin cancers excluding melanoma will be eligible for participation)",{"count":443,"type":22},10,[52],"This phase I trial tests whether fluoxetine (prozac) works to modify the tumor immune cells before surgery in patients with colorectal cancer. Fluoxetine is a commonly used selective serotonin reuptake inhibitor (SSRI) prescribed for major depressive disorder and generalized anxiety. Giving fluoxetine may modify the immune cell composition in the tumor and its microenvironment and may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread in patients with colorectal cancer.",[447],"Colorectal Adenocarcinoma",{"date":356,"type":33},{"date":450,"type":33},"2025-03-20",{"date":452,"type":22},"2027-07-01",{"name":39,"class":40},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":41},"100521060","an-organoid-based-functional-precision-medicine-trial-in-osteosarcoma-100521060","NCT06064682","An Organoid-based Functional Precision Medicine Trial in Osteosarcoma","An Organoid-based Functional Precision Medicine Trial in Osteosarcoma: PREMOST","PREMOST","Inclusion \u002F exclusion criteria - Group1:\n\n\\- Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes\n\nInclusion \u002F exclusion criteria - Group 2:\n\n\\- Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes",{"count":463,"type":22},40,"The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testing, will help us to understand osteosarcoma better.",[466],"Osteosarcoma",[466],{"date":356,"type":33},{"date":470,"type":33},"2024-02-12",{"date":472,"type":22},"2028-01-01",{"name":39,"class":40},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":481,"sex":17,"minAge":482,"maxAge":319,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":493,"locationsCount":41},"100397280","a-study-to-see-if-an-iphone-weight-management-app-can-help-promote-weight-loss-in-adolescents-and-young-adults-after-a-stem-cell-transplant-100397280","NCT04453072","A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant","Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients (BWL001)","Inclusion Criteria:\n\n* Patients with a history of HSCT of any type, at least 100 days post-transplant at initial consultation of the study, will be eligible for the study\n* Patients must classify as obese, represented as body mass index (BMI) \\>= 85th percentile for age and gender\n* Patients must also be able to read English since the app intervention is only available in English form\n* No patients will be excluded for any specific underlying medical condition, but decisions will be made on a case by case basis if a patient's functioning is deemed to significantly interfere with intervention participation\n* PARENT:\n* His\u002Fher child meets all inclusion criteria\n* \\>= 18 years of age\n* Can speak English\n\nExclusion Criteria:\n\n* Patients who are \\\u003C 100 days post-transplant at initial consultation will not be eligible for the study, but may become eligible if they are \\> 100 days post-transplant at their next consultation that falls within the enrollment window\n* Patients whose BMI does not fall under the obese category will be excluded",true,"13 Years",{"count":213,"type":22},[25],"This early phase I trial studies how well a behavioral weight loss intervention consisting of a smartphone application and coaching works for the promotion of weight loss in adolescents and young adults after a stem cell transplant. This study may help researchers learn more about how adolescents and young adults can lose weight and develop healthy eating habits.",[487,488],"Obesity","Malignant Neoplasm",{"date":356,"type":33},{"date":491,"type":33},"2020-07-01",{"date":153,"type":22},{"name":39,"class":40},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":481,"sex":162,"minAge":501,"maxAge":502,"enrollmentInfo":503,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":505,"conditions":506,"keywords":509,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":41},"100385308","brain-health-in-breast-cancer-survivors-100385308","NCT04297020","Brain Health in Breast Cancer Survivors","Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine Therapy","Inclusion Criteria:\n\n* Age 35-65\n* Fluent in English\n* Adequate vision\u002Fhearing to complete testing\n\nExclusion Criteria:\n\n* History of major or mild neurocognitive disorder or dementia\n* Diagnosis of major neurological condition (e.g., epilepsy, Parkinson's Disease, stroke)\n* Diagnosis of a major psychiatric disorder (e.g., bipolar disorder, schizophrenia)\n* Untreated\u002Funstable unipolar depression or anxiety\n* Prior history of cancer or chemotherapy (for controls, any history)\n* History of a learning disorder\n* History of head injury with loss of consciousness \\>20 minutes\n* History of salpingo-oophorectomy or hysterectomy\n* A cardiac pacemaker\n* Implanted electronic device\n* Claustrophobia\n* Currently pregnant\n* Orbital metal implant or other metallic foreign bodies\n\nAdditional exclusion criteria for controls: current use of a contraceptive agent that interferes with endogenous hormonal fluctuation (e.g., oral contraceptive pill) or precludes determination of menstrual pattern (e.g., hormonally secreting intrauterine device), or current treatment with systemic estrogen replacement therapy.","35 Years","65 Years",{"count":504,"type":22},120,"Endocrine therapy (ET) is widely used to treat hormone receptor positive breast cancer and prevent recurrence by downregulating estrogen function. However, ETs readily cross the blood brain barrier and interfere with the action of estrogen in the brain. Estrogen supports cognition and menopausal status is closely linked to cognitive health in women. This has raised concern that anti-estrogen ETs may affect cognition and brain health in breast cancer survivors. However, evidence across existing studies is inconsistent and these effects remain poorly understood. The incomplete understanding of the effects of ET are likely due to limitations of earlier studies - namely, the under-appreciation of the role of menopausal status and insensitivity of standard cognitive measures. This research project will address these earlier limitations by specifically comparing ET effects by menopausal status, and using highly sensitive, task-related functional magnetic resonance imaging (fMRI) measures to assess the effects of ET on brain function.",[507,508],"Cognitive Impairment","Cognitive Function",[510,511],"Breast cancer","endocrine therapy",{"date":356,"type":33},{"date":514,"type":33},"2020-03-11",{"date":516,"type":22},"2028-03-15",{"name":39,"class":40},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":23,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":41},"100628997","phase-2-ropeginterferon-alfa-2b-for-the-treatment-of-myelodysplastic-syndromemyeloproliferative-neoplasm-overlap-syndromes-and-chronic-myelomonocytic-leukemia-100628997","NCT07468916","Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia","Ropeginterferon Alfa-2b for MDS\u002FMPN Overlap Syndromes, Including CMML and MDS\u002FMPN-RS-T","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age at time of consent\n* Documentation of a diagnosis of MDS\u002FMPN overlap syndrome based on World Health Organization (WHO) 2022 classification, including CMML, MDS\u002FMPN with neutrophilia, myelodysplastic\u002Fmyeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\u002FMPN-RS-T), or MDS\u002FMPN, not otherwise specified, by local pathology review, and deemed to potentially benefit from study participation by the investigator\n* Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study\n* Blast =\\\u003C 10% by marrow immunohistochemistry stain\n* Platelet count of \\> 50,000\u002FuL\n* Absolute neutrophils count (ANC) of \\> 1000\u002FuL\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\\\u003C 2\n* Serum creatinine =\\\u003C 2.5 mg\u002FdL\n* Serum direct bilirubin \\\u003C 2.0 mg\u002FdL\n* Serum transaminase \\\u003C 2.5 times the upper limit of the normal range (ULN) or \\\u003C 5 times ULN if the transaminase elevation was deemed related to the MDS\u002FMPN\n\nExclusion Criteria:\n\n* Prior therapy with interferon or pegylated interferon product, or azacitidine\n* Spleen overtly enlarged by physical exam (eg. greater than 5 fingerbreadth below costal margin)\n* Other standard (including erythropoietin-stimulating agents \\[ESA\\] or luspatercept) or experimental therapy for MDS\u002FMPN within 28 days of starting study therapy with the exception of hydroxyurea, which is allowed to continue up to 28 days after cycle 1 day 1 (C1D1) while on protocol\n* Clinically significant autoimmune disease by investigator assessment, regardless if the autoimmune phenomena is related to MDS\u002FMPN overlap syndrome\n* History of or current clinically relevant depression or anxiety per investigator's judgement. Previous suicidal ideation or attempts are not allowed to participate in interferon (IFN) therapy\n* Evidence of severe retinopathy or clinically relevant ophthalmological disorder\n* History of organ transplant\n* Pregnant or breastfeeding women\n* Active uncontrolled infection with clinical symptoms, e.g., presence of bacteria, fungal, human immunodeficiency virus (HIV), hepatitis B or C\n* Active uncontrolled thromboembolic complications or hemorrhage\n* History of any malignancy within 5 years (except adequately treated non-melanoma skin cancer, prostate cancer status post resection with an undetectable prostate-specific antigen \\[PSA\\], curative treated in-situ cancer of the cervix, ductal carcinoma in situ \\[DCIS\\] of the breast, stage 1 grade 1 endometrial carcinoma, or other solid tumors including lymphomas curatively treated with no evidence of disease for ≥ 1 year prior to study)\n* Uncontrolled active clinically significant illness that, in the investigator's opinion, may affect the patient's participation in this study\n* Active abuse of alcohol and\u002For illicit drugs",{"count":526,"type":22},35,[53],"This phase II trial tests the safety, best dose, and effectiveness of ropeginterferon alfa-2b for the treatment of patients with myelodysplastic syndrome\u002Fmyeloproliferative neoplasm overlap syndromes and chronic myelomonocytic leukemia. Ropeginterferon alfa-2b is a form of interferon. Interferons are a type of signaling protein normally produced by the body as part of the immune response. Interferons interfere with the division of cancer cells and can slow cancer cell growth. Ropeginterferon alfa-2b is a long-acting form of a type of interferon called interferon alfa-2b. In the body, ropeginterferon alfa-2b causes the production of proteins that modulate the immune system and have anticancer effects.",[530,531,532,533,534],"Atypical Chronic Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic\u002FMyeloproliferative Neoplasm","Myelodysplastic\u002FMyeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","Myelodysplastic\u002FMyeloproliferative Neoplasm, Not Otherwise Specified","2026-05-05",{"date":537,"type":33},"2026-05-06",{"date":539,"type":22},"2026-09-29",{"date":541,"type":22},"2032-09-30",{"name":39,"class":40},{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":23,"phases":551,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":41},"100617824","phase-2-telisotuzumab-vedotin-and-osimertinib-for-the-treatment-of-progressive-incurable-non-small-cell-lung-cancer-100617824","NCT07323641","Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","A Phase II Trial of Telisotuzumab Vedotin With Osimertinib for EGFR Mutated NSCLC With c-MET Overexpression That is Progressing on Osimertinib","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age and willing and able to provide informed consent\n* Cytologically or histologically confirmed non small cell lung cancer (NSCLC), which is incurable with an activating and sensitizing EGFR mutation (e.g., exon 20 insertion mutations are excluded). Enrollment of patients with mutations other than exon 19 deletion and the L858R point mutation require literature supporting sensitivity to osimertinib. T790M mutations and identified EGFR mutations that are known to confer resistance to osimertinib (for instance C797S) are allowed\n* Predominantly adenocarcinoma histology. (Small cell or predominantly squamous cell or sarcomatoid\u002Fpleiomorphic histologies are excluded.)\n* Progressed on osimertinib. Osimertinib must have been included in the last systemic therapy prior to trial enrollment and the patient must be considered appropriate for continuation of osimertinib at 80 mg daily per the treating investigator\n* From a tumor specimen obtained following progression on osimertinib or within 4 months of study entry (as long as the specimen was obtained after osimertinib was started), subjects must have c-MET overexpressing NSCLC as assessed by a Certified Laboratory Improvement Amendments (CLIA)-certified laboratory using the VENTANA MET (SP44) RxDx assay, with intermediate or high expression, defined as either ≥ 25% and \\\u003C 50% (intermediate) or ≥ 50% (high). If local results are unavailable, central testing may be performed\n* Measurable disease, as per RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Able to swallow the oral study drug, has no known intolerance of study drugs or excipients, and able to comply with study requirements\n* Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL\n* Platelets ≥ 100 × 10\\^9\u002FL\n* Hemoglobin ≥ 9 g\u002FdL\n* Serum creatinine ≤1.5 X upper limit of normal (ULN) OR measured or calculated\\* creatinine clearance ≥ 50 mL\u002Fmin (glomerular filtration rate \\[GFR\\] can also be used in place of creatinine or creatinine clearance \\[CrCl\\])\n\n  * Creatinine clearance may be calculated using a 24 hour urine collection, by the Cockcroft-Gault formula or estimated glomerular filtration rate (eGFR) per the Modification of Diet in Renal Disease (MDRD) GFR equation\n* Serum total bilirubin ≤ 1.5 X ULN OR direct bilirubin ≤ ULN\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 2.5 X ULN OR ≤ 5 X ULN for participants with liver metastases\n* Albumin ≥ 3.0 g\u002FdL\n* Female participants of childbearing potential must have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum test must be negative for pregnancy for the participant to be eligible. Female participants must agree to use a highly effective method of contraception from the beginning of screening until 7 months after the last dose of the telisotuzumab vedotin, or be of nonchildbearing potential.Nonchildbearing potential is defined as follows (by other than medical reasons):\n\n  * ≥ 45 years of age and has not had menses for \\> 2 years, in the absence of conditions that could lead to amenorrhea (i.e., post chemotherapy),\n  * Participants who have been amenorrhoeic for \\\u003C 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation, or\n  * Surgical sterilization (Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation)\n* Male patients having sex with a female partner of childbearing potential or a pregnant or breastfeeding partner must agree to use barrier contraception (male condom) for the duration of the treatment period until 4 months after the last dose of telisotuzumab vedotin\n* Male and female participants must agree not to donate sperm or eggs, respectively starting from the first study-drug treatment, Men must not donate sperm during trial therapy and for 4 months after receiving the last dose of study medication and women must not donate eggs during trial treatment and for 7 months after receiving the last dose of study medication\n\nExclusion Criteria:\n\n* Concurrent enrollment in another clinical study, unless enrolled only in the follow-up period or an observational study\n* Prior c-MET targeted antibody drug conjugate with a microtubule toxin (such as monomethylauristatin E \\[MMAE\\]). Prior MET antibody without a toxin, prior MET antibody drug conjugate (ADC) with a non-microtubule, and prior MET TKI therapy are acceptable\n* Any chemotherapy, immunotherapy, biologic, hormonal therapy, or investigational systemic therapy for cancer treatment in the prior 3 weeks or within 5 half-lives of the medication, whichever is shorter. Concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable\n* Thoracic radiation of ≥ 30 grey (Gy) within 6 months. Other radiation within 2 weeks with the exception: Stereotactic, palliative radiation for bone metastases is acceptable without a washout as long as no lung parenchyma was included in the radiation field\n* Progressive or symptomatic brain metastases. Brain metastases that have been radiated, are asymptomatic, and on a stable or decreasing dose of steroids are allowed. Leptomeningeal disease is excluded\n* Has not recovered (recovery is defined as National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events \\[CTCAE v 5.0\\] grade ≤ 1) from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting the inclusion requirements stated in the inclusion criterion. Other grade 2 or less toxicities not constituting a safety risk based on the investigator's judgment are acceptable.\n\n  * Subjects with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for the study\n* Subject must not have a history of idiopathic lung disease, drug-induced idiopathic lung disease, idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, radiation pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan\n* Major surgical procedures or serious trauma within 4 weeks prior to cycle (C) 1 day (D) 1, or plans for major surgical procedures within 4 weeks after the first dose (as determined by the investigator). Minor local procedures (excluding central venous catheterization and port implantation) do not require a washout\n* The patient has any ongoing or active infection requiring the use of parenteral anti-microbial agents. Patient with a history of HIV with an undetectable viral load and a CD4 count over 200 are eligible. Patients with a history of hepatitis B or hepatitis C, an undetectable viral load, and liver function tests (LFT) testing which meets criteria for the study are eligible\n* History of another cancer within 2 years of study initiation, with the exception of fully treated cancers unlikely to affect the assessment of the study treatment safety or efficacy including early-stage breast, prostate, bladder, non-melanomatous skin, thyroid, cervical, or endometrial cancer. Additionally, subjects must not be receiving any ongoing anti-cancer therapy, including maintenance therapy, prior to randomization. Hormonal therapy is allowed provided that the participant otherwise meets trial criteria\n* Participants must not be considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to uncontrolled ventricular arrhythmia, myocardial infarction within 6 months, stroke within 6 months, clinically significant electrocardiogram (ECG) abnormalities, any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as electrolyte abnormalities, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis, grade ≥ 2 edema or lymphedema, grade ≥ 2 ascites or pleural effusion, grade ≥ 2 neuropathy, grade ≥ 2 corneal disorder as assessed by a baseline ophthalmic exam, or any psychiatric disorder that prohibits obtaining informed consent\n* Patient unwilling or unable to comply with the protocol\n* Any condition that, in the opinion of the investigator or sponsor-investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results",{"count":21,"type":22},[53],"This phase II trial tests how well telisotuzumab vedotin and osimertinib works for the treatment of non small cell lung cancer that is growing, spreading, or getting worse (progressive) and for which no treatment is currently available (incurable). Telisotuzumab vedotin is a monoclonal antibody, called telisotuzumab, linked to a toxic agent, called vedotin. Telisotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as c-Met receptors, and delivers vedotin to kill them. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving telisotuzumab vedotin and osimertinib may be effective for treating progressive, incurable non small cell lung cancer.",[554],"Lung Non-Small Cell Carcinoma","2026-04-15",{"date":557,"type":33},"2026-04-20",{"date":559,"type":33},"2026-02-19",{"date":561,"type":22},"2028-02-01",{"name":39,"class":40},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":41},"100632709","a-prospective-study-of-physical-function-in-adults-who-receive-systemic-therapy-for-stage-i-iii-gastroesophageal-cancer-fast-go-study-100632709","NCT07517211","A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study","A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer (FAST-GO)","Inclusion Criteria:\n\n* \\* Adults ≥ 18 years old at the start of study treatment.\n\n  * New diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma.\n  * Plan to start systemic therapy for resectable or potentially resectable disease.\n  * Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* \\* Patients with stage I disease with plans to undergo endoscopic resection or surgery alone without perioperative systemic therapy.\n\n  * Metastatic disease at the time of diagnosis.\n  * Patients who are unable to provide informed consent.\n  * Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n  * Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, increase muscle strength, or improve cognitive function.",{"count":571,"type":22},72,"This study evaluates how the treatment for gastroesophageal cancer affects physical function in patients who receive chemotherapy as part of their treatment for gastroesophageal cancer.",[574,417,418,419,420,421,422,423,424,425,426,427],"Clinical Stage I Esophageal Adenocarcinoma AJCC v8","2026-04-03",{"date":577,"type":33},"2026-04-08",{"date":579,"type":22},"2026-05-01",{"date":581,"type":22},"2029-05-01",{"name":39,"class":40},""]